[HTML][HTML] Biosimilars in the United States: considerations for oncology advanced practitioners
KD Mayden, P Larson, D Geiger… - Journal of the Advanced …, 2015 - ncbi.nlm.nih.gov
Biosimilars will enter the US market soon, potentially lowering costs and increasing patient
access to important oncology biologics. Biosimilars are highly similar, but not identical, to …
access to important oncology biologics. Biosimilars are highly similar, but not identical, to …
Biosimilars in the United States: Considerations for Oncology Advanced Practitioners.
KD Mayden, P Larson, D Geiger… - Journal of the Advanced …, 2015 - europepmc.org
Biosimilars will enter the US market soon, potentially lowering costs and increasing patient
access to important oncology biologics. Biosimilars are highly similar, but not identical, to …
access to important oncology biologics. Biosimilars are highly similar, but not identical, to …
Biosimilars in the United States: Considerations for Oncology Advanced Practitioners
KD Mayden, P Larson, D Geiger… - Journal of the …, 2015 - pubmed.ncbi.nlm.nih.gov
Biosimilars will enter the US market soon, potentially lowering costs and increasing patient
access to important oncology biologics. Biosimilars are highly similar, but not identical, to …
access to important oncology biologics. Biosimilars are highly similar, but not identical, to …